Skip to main content

Site notifications

RAPIVAB peramivir 200 mg / 20 mL concentrate for intravenous infusion glass vial, Biocelect Pty Ltd, CON-870

Product name
RAPIVAB peramivir 200 mg / 20 mL concentrate for intravenous infusion glass vial
Sponsor name
Biocelect Pty Ltd
Batches
C2000129
Consent start
Consent no.
CON-870
Standard
Paragraphs 8(1)(d), 8(1)(f), 8(1)(g), 8(1)(h), 9(1)(g) and 9(3)(a); and Subparagraphs 10(3)(a)(i) of Therapeutic Goods Order No. 91 '“ Standard for labels of prescription and related medicines (TGO 91)
Non-compliance with standard
The product does not conform with the requirements of Section 6 'main label'; Paragraphs 8(1)(d), 8(1)(f), 8(1)(g), 8(1)(h), 9(1)(g) and 9(3)(a); and Subparagraphs 10(3)(a)(i) of TGO 91 in that the product packaging does not comply with the following ' The carton label does not include the medicine name more conspicuously on the main panel; does not include the approved name of the dosage form 'Concentrated Injection'; does not indicate the location of the batch and expiry prefixes; does not include the statement 'Protect from light'; does not include the words 'for infusion' adjacent to the name of the dosage form; does not include the name and quantity of the active ingredient together on one line immediately below the medicine name; and does not state the amount of the excipient 'sodium chloride' in the volume of fill of the injection in the container (i.e. 20 mL). ' The vial label does not include the approved name of the dosage form 'Concentrated Injection'; does not indicate the location of the batch and expiry prefixes; and does not include the statement 'Protect from light'.
Conditions imposed
1. A 'Dear Healthcare Professional' letter identical to that provided   in the email correspondence to the Therapeutic  Goods  Administration  dated 22 September 2021 will be supplied with each affected batch outlining the non-compliance in the product labelling. 2. The labels to which this consent applies are those provided  in the email correspondence to the  Therapeutic  Goods  Administration  dated 22 September 2021     
Therapeutic product type
Prescription medicines

Help us improve the Therapeutic Goods Administration site